Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • Siemens Healthineers...

    Siemens Healthineers receives FDA clearance for Epoc BUN, TC02 tests

    Written by Ruby Khatun Khatun Published On 2018-02-05T09:45:16+05:30  |  Updated On 5 Feb 2018 9:45 AM IST
    Siemens Healthineers receives FDA clearance for Epoc BUN, TC02 tests

    MALVERN, Pa.: Siemens Healthineers announced it has received 510(k) clearance from the U.S. Food and Drug Administration for its Blood Urea Nitrogen (BUN) and Total Carbon Dioxide (TCO2) point-of-care tests to aid in the diagnosis of renal diseases and metabolic imbalances. These assays expand precision medicine performed at the patient-side to enable faster clinical decision making.


    In its continued effort to improve patient care, Siemens Healthineers now can provide a full menu on a single test card within the blood analysis market for clinicians to perform at the patient bedside on the handheld epoc® Blood Analysis System. A broad menu benefits clinical service lines that routinely perform blood analysis, including critical care units, the emergency department, radiology, cardiac catheterization labs and out-patient centers.


    “With the epoc system, these new assays will expand the patient information clinicians can access sooner to help rule in or rule out potential diagnoses more quickly,” said Michael Sampson, Senior Vice President, Point of Care Diagnostics, North America, Siemens Healthineers. “Rapid informed diagnoses and treatment decisions at the patient-side ultimately aids in improving clinical outcomes.”


    BUN—combined with creatinine and an estimated glomular filtration rate (eGFR)—also available on the epoc system—can aid in the differential diagnosis of renal and metabolic diseases. TCO2—with other parameters that comprise a basic metabolic panel currently available at the point of care from Siemens Healthineers—can aid clinicians in assessing acid-base and metabolic imbalances and make changes in therapy where necessary.


    The epoc® Blood Analysis System delivers a full menu of results, including pH, partial pressure of oxygen, partial pressure of carbon dioxide, sodium, potassium, ionized calcium, hematocrit, glucose, lactate, creatinine, chloride, and soon BUN and TCO2, in less than a minute. Results are easily integrated into any Laboratory Information System.

    Blood Urea Nitrogenclearanceepoc Blood Analysis SystemEpoc BUNFDAmetabolic imbalancesMichael Sampsonreceivesrenal diseasesSiemensSiemens HealthineersTC02 testsTotal Carbon Dioxide
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok